Free Trial

Beta Bionics (NASDAQ:BBNX) Trading Down 5.4% - What's Next?

Beta Bionics logo with Medical background

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) was down 5.4% on Tuesday . The company traded as low as $18.39 and last traded at $18.39. Approximately 45,941 shares traded hands during trading, a decline of 91% from the average daily volume of 492,952 shares. The stock had previously closed at $19.45.

Analysts Set New Price Targets

Several analysts recently issued reports on BBNX shares. Robert W. Baird began coverage on Beta Bionics in a research note on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target for the company. Baird R W raised Beta Bionics to a "hold" rating in a report on Thursday, February 20th. Bank of America began coverage on shares of Beta Bionics in a research note on Monday, February 24th. They issued a "buy" rating on the stock. Piper Sandler started coverage on shares of Beta Bionics in a research report on Monday, February 24th. They set an "overweight" rating and a $26.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on shares of Beta Bionics in a research note on Friday, May 30th. They issued a "neutral" rating and a $16.00 price objective for the company. Four analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.44.

View Our Latest Analysis on Beta Bionics

Beta Bionics Stock Performance

The stock has a 50 day moving average price of $14.65.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $17.89, for a total transaction of $26,781.33. Following the completion of the transaction, the chief financial officer now owns 45,503 shares of the company's stock, valued at approximately $814,048.67. The trade was a 3.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 4,519 shares of company stock valued at $80,845.

Institutional Investors Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Strs Ohio acquired a new stake in Beta Bionics in the first quarter valued at approximately $29,000. Corebridge Financial Inc. bought a new position in shares of Beta Bionics in the 1st quarter valued at $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Beta Bionics in the 1st quarter valued at $95,000. MetLife Investment Management LLC acquired a new stake in shares of Beta Bionics during the 1st quarter valued at $102,000. Finally, Deutsche Bank AG bought a new stake in Beta Bionics during the 1st quarter worth $148,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Further Reading

Should You Invest $1,000 in Beta Bionics Right Now?

Before you consider Beta Bionics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.

While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines